Xiaolan Deng
Impact in
- Molecular Biology top 0.5%
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- RNA Research and Splicing
- Circular RNAs in diseases
- Cancer Research top 2%
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
Papers in
-
- RNA modifications and cancer 27
- Epigenetics and DNA Methylation 3
-
- Analytical Methods in Pharmaceuticals 5
- Co-authors
- Jianjun Chen (14 shared papers)Rui Jun Su (7 shared papers)Huilin Huang (3 shared papers)Hengyou Weng (2 shared papers)Zejuan Li (1 shared paper)Ying Qing (4 shared papers)David Horne (1 shared paper)Yusuke Nakamura (5 shared papers)
- Journals
- Cell stem cell (4 papers)Journal of Separation Science (3 papers)Cell (3 papers)Nature Cell Biology (2 papers)Cancer Cell (2 papers)
- Partner nations
- ChinaUnited StatesBelgium
In The Last Decade
Xiaolan Deng
64 papers receiving 9.3k citations
Xiaolan Deng's Hit Papers
Peers
Comparison fields: 5 of 129
- Molecular Biology 7.6k
- Cancer Research 690
- Hematology 316
- Oncology 368
- Genetics 111
Countries citing papers authored by Xiaolan Deng
This map shows the geographic impact of Xiaolan Deng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaolan Deng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaolan Deng more than expected).
Fields of papers citing papers by Xiaolan Deng
This network shows the impact of papers produced by Xiaolan Deng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaolan Deng. The network helps show where Xiaolan Deng may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaolan Deng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 65 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation Hit paper breakdown → | 2018 | 2336 |
| 2 | R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling Hit paper breakdown → | 2017 | 941 |
| 3 | METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification Hit paper breakdown → | 2017 | 827 |
| 4 | RNA N6-methyladenosine modification in cancers: current status and perspectives Hit paper breakdown → | 2018 | 661 |
| 5 | Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion Hit paper breakdown → | 2020 | 618 |
| 6 | Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally Hit paper breakdown → | 2019 | 558 |
| 7 | 2020 | 310 | |
| 8 | The roles and implications of RNA m6A modification in cancer Hit paper breakdown → | 2023 | 270 |
| 9 | METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis Hit paper breakdown → | 2022 | 266 |
| 10 | The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia Hit paper breakdown → | 2022 | 263 |
| 11 | R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis Hit paper breakdown → | 2021 | 257 |
| 12 | FTO in cancer: functions, molecular mechanisms, and therapeutic implications Hit paper breakdown → | 2022 | 190 |
| 13 | 2017 | 173 | |
| 14 | 2023 | 139 | |
| 15 | 2023 | 131 | |
| 16 | 2018 | 112 | |
| 17 | 2022 | 112 | |
| 18 | 2023 | 80 | |
| 19 | 2016 | 69 | |
| 20 | 2019 | 68 |
About Xiaolan Deng
Xiaolan Deng is a scholar working on Molecular Biology, Analytical Chemistry, Cancer Research, Hematology and Spectroscopy, having authored 65 papers that have together received 9.4k indexed citations. Recurring topics across this work include RNA modifications and cancer (27 papers), Acute Myeloid Leukemia Research (5 papers), Analytical Methods in Pharmaceuticals (5 papers), Analytical Chemistry and Chromatography (4 papers), Acute Lymphoblastic Leukemia research (3 papers), Epigenetics and DNA Methylation (3 papers), Cancer-related molecular mechanisms research (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Molecular Biology (7.6k citations), Cancer Research (690 citations), Hematology (316 citations), Oncology (368 citations) and Genetics (111 citations). Xiaolan Deng has collaborated with scholars based in China, United States and Belgium. Frequent co-authors include Jianjun Chen, Rui Jun Su, Huilin Huang, Hengyou Weng, Zejuan Li, Ying Qing, David Horne, Yusuke Nakamura, Minjie Wei and Yangchan Li. Their work appears in journals such as Cell stem cell, Journal of Separation Science, Cell, Nature Cell Biology and Cancer Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.